Point of Care Testing for Presence of Current and or Previous T. Gondii Infection
Status
Conditions
Treatments
Details and patient eligibility
About
This is part of a feasibility study to compare the predicate standard FDA cleared test for serum to a point of care test Toxoplasma ICT IgG-IgM BK produced by LD Bio Diagnostic. The specificity and sensitivity in testing serum and whole blood will be compared. This study includes 70 persons either pregnant or non pregnant.
This is being done in accordance with FDA requirements for clearance of a testing device . The investigators will use a standard FDA cleared test in all studies. The FDA has suggested that the investigators submit a pre subQ for a 510K and dual CLIA waiver.
This allows the investigators also to determine feasibility of use of the predicate test in conjunction with the experimental test with volunteers, including men, women, and pregnant women.
Full description
This study will determine the feasibility of using the point of care Toxoplasma ICT IgG-IgM BK test produced by LD Bio Diagnostic to detect Toxoplasma gondii in clinical settings. The result of testing from Toxoplasma ICT IgG-IgM BK test will be compared with the standard predicate test. These results will be provided to FDA for consideration for clearance of this test.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- any adult who is willing to participate in the study
Exclusion criteria
- pregnant women who are in their 17-27 weeks of gestation.
Trial design
Primary purpose
Allocation
Interventional model
Masking
210 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Marcela Cid; Rima McLeod, M.D.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal